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The aggressiveness of a tumour is primarily dependent on its
ability to invade adjacent tissue and to metastasize to distant sites.
Proteolytic degradation of the basement membrane and the extra-
cellular matrix is a central aspect of physiologic and pathologic
tissue-remodelling processes, such as neovascularization, wound
healing, and malignant growth. Various proteolytic enzymes such
as matrix-metalloproteinases (MMPs), serine proteinases and
cathepsins have been implicated in the proteolytic process (Dano
et al, 1994; Chambers et al, 1997; Benaud et al, 1998; Yan et al,
1998; Nelson et al, 2000; Scorilas et al, 2000a and b; Magklara 
et al, 2000; Yousef et al, 2000; Yousef et al, 2001). Digestion of
the subendothelial basement membrane is the first step towards
intravasation and extravasation of cancer cells. Type IV collagen is
the main component of the basement membrane and degradation
of this structural protein is favoured by two metalloproteases,
namely the 72kDa type IV collagenase (MMP-2, gelatinase A) and
the 92kDa type IV collagenase (MMP-9, gelatinase B). 
The in vivo origin of MMPs remains ambiguous, since MMP-2
production has been observed in fibroblasts, osteoblasts, endothe-
lial cells and macrophages, while MMP-9 has been observed in
polymorphonuclear leukocytes, vascular pericytes, macrophages
and keratinocytes (Nielsen et al, 1996a, 1997; Sugiura et al, 1998).
In breast cancer, immunohistochemical studies have indicated 
that MMP-2 is expressed in both normal and malignant 
breast tissue and MMP-9 in macrophages located adjacent to 
the invading tumour front (Tryggvason et al, 1993) and 
tumour cells (Jones et al, 1999). MMPs are secreted as 
inactive proenzymes. Pro-MMP-2 is activated in vitro on the cell
surface by a membrane-type matrix metalloprotease (MT-MMP)
(Strongin et al, 1995). Several enzymes can activate pro-MMP-9 in
vitro, including interstitial collagenase (MMP-1), stromelysin-l
(MMP-3), matrilysin (MMP-7) and MMP-2 (Friedman et al, 
1995); nevertheless, little is known about the activation 
mechanism in vivo. Activity of MMPs is also regulated by tissue
inhibitors of metalloproteases (TIMPs) (Blavier et al, 1996). In
vivo expression studies of the MMPs and TIMPs indicate that
stromal cells in several types of cancer contribute by synthesizing
these proteins (Hewitt et al, 1996; Heppner et al, 1996; Sugiura 
et al, 1998). Furthermore, components of the plasminogen activation
system, such as PAI-1, are expressed by stromal cells in breast cancer
(Bianchi et al, 1995; Nielsen et al, 1996b). The imbalance between
MMPs and TIMPs resulting from increased production and activa-
tion of MMPs plays an important role in the invasiveness of the
cancer (Liotta et al, 1991). 
Several MMP family members have been specifically impli-
cated in the progression of breast cancer. However, the regulation
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of MMP expression and activity in tumours appears complex and
the manner in which MMPs collectively contribute to breast
tumour progression is not well understood. In general, the induc-
tion of MMPs in the stroma within tumours and in adjacent normal
tissue represents a direct or indirect host response to the presence
of tumour cells (Heppner et al, 1996). With regard to MMP-9,
many reports show that it is expressed in breast cancer tissue, but
there are conflicting results regarding the identity of the cells that
express this protease (Visscher et al, 1994; Heppner et al, 1996;
Nielsen et al, 1996a, 1997). Although the expression of MMP-9 in
breast tumour tissue has been examined by different methods,
namely ELISA (Duffy et al, 1995), northern blotting (Pacheco 
et al, 1998), zymography (Rha et al, 1997, 1998), in situ hybridiza-
tion (Nielsen et al, 1997) and immunohistochemistry (Nielsen 
et al, 1997) but to the best of our knowledge, survival analysis
connecting MMP-9 expression with disease outcome has not been
performed with enough samples to produce statistically significant
results. 
In this study we examined the expression of MMP-9 using
immunocytochemistry in 210 Greek cancer patients, correlated it
with clinicopathological disease variables, and evaluated its prog-
nostic value. To our surprise, this expression was associated with
pathologic and biochemical features of less aggressive disease,
and with a favourable prognosis. Similar reports by other groups
have attributed favorable prognosis to the expression of other
proteases like PSA (Yu et al, 1998) and Pepsinogen C (Scorilas 
et al, 1999c) in breast cancer patients, although their findings have
not been fully explained until now. 
MATERIALS AND METHODS 
Tissue samples and patients 
Tumour samples from 210 patients who underwent surgery for
primary breast cancer between 1989 and 1993 at the Oncologic
Hospital of Athens ‘St Savas’ and at the ‘401 Army Hospital’ were
evaluated in this study. Ten breast tissue samples from individuals
confirmed to be free of malignancy were analysed for negative
control purposes. Tumour specimens were randomly drawn from a
pool of frozen specimens originally submitted to the Laboratory of
Hormone Receptors for steroid receptor analysis. A computerized
database of updated patient clinical data, in addition to receptor
status, nodal status and number of positive nodes, primary tumour
diameter, age and menopausal status of the patients, and/or differ-
entiation grade of the tumour, was available for statistical analysis. 
All patients had a histologically confirmed diagnosis of primary
breast cancer and received no treatment before surgery. Surgery
consisted of modified mastectomy (87 patients) or breast
conserving lumpectomy (123 patients). Axillary lymph node
dissection was performed on 96% of the patients. For these
patients, the positivity rate for cancer involvement of lymph nodes
was 57.7%. Tumour size ranged from 0.6 to 7.0 cm in diameter,
the mean and median being 2.9 cm and 2.7 cm, respectively.
Clinical staging was performed according to the Postsurgical
International Union Against Cancer Tumour-Node-Metastasis
classification system (Spiessl et al, 1989). Of the 206 patients for
whom the stage was known, 24(11.6%), 135(65.5%), 42(20.4%)
and 5(2.5%) were classified as Stage I, II, III and IV, respectively.
Histologic grade of the tumours was known for 202 patients and
was as follows, according to the criteria reported by
Scarff–Bloom–Richardson (Doussal et al, 1989): 9 patients (4.5%)
had grade I, 164 (81.2%) had grade II and 29 patients (14.3%) had
grade III tumours. Most of the tumours for which the histologic
type was known (178 patients) were invasive ductal (88.8%),
whereas the remaining were invasive lobular (8.4%) and other
histologic types (2.8%). The post-operative treatment modality
was known for all patients; 4.8% received no further treatment
after tumour resection, 28.0% were given adjuvant chemotherapy,
59.0% were treated with endocrine therapy, and 8.2% were given
both chemotherapy and endocrine therapy. Postoperative locore-
gional radiotherapy was administered to 148 patients. Disease
relapse was defined as the first documented evidence of local or
regional axillary recurrence or distant metastasis. 
Patient age ranged from 24 to 94 years; the median age being 56
years. Twenty-one percent of the patients were under the age of 45,
19% were between 45 and 55, and 60% were 56 years or older.
Follow-up information was available for 206 patients and included
survival and relapse status, with the dates of the events and cause
of death, if applicable. The distribution of follow-up times for
patients still alive at the time of analysis ranged from 24 to 83
months, with a median of 68 months; only 6 and 2 patients had
been followed less than 48 and 36 months, respectively. Follow-up
times for the entire cohort, however, ranged from 10 to 85 months
and had a median of 62 months. The Relapse-free survival (RFS)
time in each case was the time interval between the date of surgical
removal of the primary cancer and the date of the first documented
evidence of relapse. The overall survival (OS) time was the time
interval between the date of surgery and the date of death, or the
date of last follow-up for those who were alive at the end of the
study. 
Immunohistochemistry 
The indirect immunoperoxidase method was adopted for
immunostaining using routinely processed paraffin embedded
specimens. Tissue sections (5 mm in thickness) were microwave-
treated for 10 min in PBS after deparaffinization and rehydration.
Endogenous peroxidase activity was blocked with 3% H2O2 in
methanol for 8 min, followed by two 5 min washes with PBS. The
tissue sections were incubated with normal goat serum for 20 min,
and then with the primary sheep anti-MMP-9 antibody (Biodesign
International Cat # k90163C USA) at a working dilution of
1:1000. Fifty of the sections were stained as well with the poly-
clonal antibody MMP-9(C-20):sc6840(Santa Cruz Biotechno-
logy). Sections were washed twice for 5 min with PBS and
incubated for 30 min with a biotinylated secondary antibody
(Vectastain ABC Elite Kit, Vector Laboratories, CA, USA) diluted
1:200 in PBS. Sections were washed twice for 5 min with PBS,
developed for 5 min with 0.05% 3,3-diaminobenzidine tetrahy-
drochloride (DAB) (Sigma, UK), slightly counterstained with
haematoxylin, dehydrated, cleared and mounted with DePex
(BDH, Limited Poole, UK). Specificity of the immunocytochem-
ical reaction was tested by pre-absorption of the anti-MMP-9 anti-
body with the purified antigen from polymorphonuclear
leukocytes (Elashry–Stowers et al, 1988) which completely abol-
ished the specific staining. Negative controls had the primary anti-
body omitted and replaced by PBS. MMP-9 immunoreactivity was
evaluated using the Image Analysis System 2000 (Digital Image
System Hellas) as described (Karameris et al, 1997). In each case,
20 optical fields of high magnification (´ 400) were measured and
300 cells were counted. All samples were evaluated for MMP-9
expression by two pathologists who were unaware of patient1490 A Scorilas et al
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outcome. Staining intensity was classified from 0 (no staining) to 3
(very strong staining). For each slide, a value designated HSCORE
was obtained by application of the following algorithm: HSCORE
=∑ [(I + 1) ´ PC], where I and PC represent intensity and
percentage cells that stain at each intensity, respectively.
Reproducibility of the scoring method between both observers was
greater than 95%. In the remaining cases in which discrepancies
had been noted, differences were established by agreement review
of corresponding slides (Karameris et al, 1997; Vizoso et al, 1995). 
Immunoabsorption of MMP-9 
Described previously by Elashry–Stowers et al, 1988, in brief,
protein A-Sepharose (Sigma) was precoated with secondary
rabbit-anti-mouse IgG (Dako) and unbound IgG was removed by
washing. IgG-coated protein A-Sepharose was then incubated with
MMP-9 antibody and then washed to remove any free antibody.
Purified MMP-9 antigen(MMP-9, human neutrophil granuloside,
Oncogene Science) was then incubated with antibody-coated
protein A-Sepharose. After incubation protein A-Sepharose beads
were washed. Beads were centrifuged and the supernatant used for
immunohistochemical staining after concentration. 
Hormone receptors 
Estrogen receptors (ER) and progesterone receptors (PR) were
assayed by the charcoal method as previously described (Kute 
et al, 1980). Results were expressed as specific binding sites per
mg of cytosolic protein (fmol/mg protein). Tumours with estrogen
and progesterone receptor concentrations below or equal to 10
fmol/mg protein were considered receptor negative, tumours with
receptor concentrations between 10 and 300 fmol/mg protein were
considered positive, whereas concentrations above that value were
characterized as strongly positive. 
Cathepsin-D 
Cathepsin-D was assayed using an immunoradiometric kit (Elsa
Cath-D kit. CIS Bio International. Gif-sur-Yvette, France)
according to the procedure described by the manufacturer.
Reconstituted tumour cytosols were analyzed in duplicate at dilu-
tions of 1:40 and 1:80 as we described previously (Scorilas et al,
1993, 1995).
Statistical analysis 
An optimal cut-off point equal to 48th percentile was defined
using chi-square (c2) analysis based on the ability of MMP-9
expression to predict the RFS and OS for the population studied.
Relationships between MMP-9 status and other variables were
analyzed using the c2 test, as well as the Fisher’s exact test, where
appropriate. ER and PR values were categorized into negative,
positive and strongly positive as described above. Tumour size
was classified as smaller than 2 cm in diameter, between 2 and 5
cm, or larger than 5 cm. Lymph node status was either positive
(histological evidence of tumour extension to one or more lymph
nodes) or negative. Patient age was categorized into three groups:
less than 45 years, 45 to 55 years and greater than 55 years.
Survival analyses were performed by constructing Kaplan–Meier
RFS and OS curves (Kaplan and Meier, 1958), where differences
between curves were evaluated by the log-rank test. Cox regression
analyses using the SAS statistical software (SAS Institute, 
Cary, NC) was used to calculate the relative risk (RR) and 95%
confidence interval (CI). Only patients for whom the status of all
variables was known were included in the multivariate models,
which incorporated MMP-9 status and all other variables for
which the patients were characterized. 
RESULTS 
Expression of MMP-9 in breast tissues 
MMP-9 expression in breast tissues was analysed by immuno-
histochemical staining using a sheep polyclonal antibody. In
breast tumours, MMP-9 expression was observed primarily
(~80%) in cancer cells, and secondly in stromal cells (Figures 1A
and 1B). Morphological characterization suggested that three
different stromal cell types showed MMP-9 positivity:
neutrophils and macrophage-like cells in all samples, and
vascular cells in 68% of samples. The expression of MMP-9 was
homogeneous, cytoplasmically diffuse, and occasionaly
membranous as seen by intense staining in parts of the membrane
(Figure 1C).
MMP-9 expression and relationship to other prognostic
variables 
MMP-9 status was evaluated in 210 breast tumours and 10 non
malignant breast tissue samples. An optimal cut-off value was
C AB
Figure 1 (A) Cytoplasmic expression of MMP-9 by tumour cells in infiltrating ductal breast carcinoma. Immunohistochemical staining ´ 200, DAB staining. 
(B) Positive mainly tumour and few stromal cells against MMP-9, in infiltrating breast carcinoma. Immunohistochemical staining ´ 100, DAB chromogen. 
(C) Dense membranous and cytoplasmic staining against MMP-9 in tumour cells of breast carcinoma. Immunohistochemical staining ´ 250, DAB 
chromogenMMP-9 in breast cancer 1491
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defined by c2 analysis, based on the ability of MMP-9 expression
to predict the RFS and OS for the population studied. As shown in
Figure 2, HSCORE value of 175 is shown to be the optimal cut-off
(c2 = 5.61, P = 0.02 and c2 = 6.74, P < 0.01 for RFS and OS,
respectively). This cut-off (48th percentile) identifies 52% and
48% of tumours as being MMP-9 positive and MMP-9 negative,
respectively. Over-expression of MMP-9 in normal breast tissue
was not observed. MMP-9 negative tumours tended to be larger in
size (P = 0.014), histologically classified as invasive ductal 
(P = 0.037), PR-negative and PR-strong positive tumours 
(P < 0.001), and obtained from patients who were diagnosed with
stage III–IV disease (P = 0.009) and were between the ages of 45
and 55 (P = 0.011). No significant association between MMP-9
status and tumour grade, nodal status, ER, and Cathepsin D was
observed (Table 1). 
MMP-9 status and breast cancer survival 
Univariate and Multivariate Analysis. Follow-up information was
available for 206 of the 210 patients included in the study. During
their respective follow-up periods, 77 patients (37.3%) relapsed
and 49 (23.8%) died. Cox univariate survival analysis revealed
that, the risk for relapse and death was significantly weak in rela-
tion to MMP-9 considered as a dichotomous variable (Table 2).
These regression models showed that there was a reduction in risk
for relapse and death in patients whose tumours showed MMP-9
positivity, compared to those which were MMP-9 negative. The
Kaplan-Meier survival curves (Figure 3) also showed that MMP-9
positivity was associated with relapse-free survival(RFS) and
overall survival(OS). In multivariate analysis, the Cox regression
models were adjusted for age, nodal status, tumor size, tumor
grade, Cathepsin-D, ER, and PR, all of which were used as cate-
gorical variables, except tumour size, which was used as a contin-
uous variable, as described above. Patient age, tumour size, ER
status and nodal status were thus shown to be independent factors
for predicting both RFS and OS. MMP-9 did not add significantly
to the prognostic power in the multivariate model for RFS and OS. 
Univariate and multivariate analysis for patients
classified by nodal status 
Since node-positive patients are substantially different from those
which are node-negative in terms of their prognosis and treatment
administered after surgery, univariate and multivariate Cox regres-
sion models were used to evaluate the effect of MMP-9 on RFS
and OS for each of the two groups of patients. The results are
shown in Table 2 and Figure 4. Node-negative breast cancer
patients with tumours positive for MMP-9 tended to have a
considerable reduction in risk for relapse (RR = 0.45; P = 0.039)
or death (RR = 0.32; P = 0.009). According to multivariate
analysis: patient age, tumour size and Cathepsin-D were found to
be independent factors for predicting both RFS and OS. MMP-9
significantly added to prognostic power in the multivariate model
of analysis for OS (RR = 0.47; P = 0.034). When the relationship
between MMP-9 and survival was examined in node-positive
patients, none of the differences were statistically significant. 
DISCUSSION 
To the best of our knowledge, this is the first paper to report an
inverse association between MMP-9 overexpression in breast
cancer and favourable prognosis in node negative patients. Using
immunohistochemistry, we have revealed that node negative
breast cancer patients whose tumours overexpress MMP-9 have a
considerable reduction in the risk for relapse or death. These unex-
pected results are difficult to explain in terms of the current
concept of the molecular mechanisms involved in tumour invasion
and metastasis. Another paradox was the poor prognosis associ-
ated with high levels of PAI-1 in breast cancer, recently resolved
by Bajou et al (1998) demonstrating that host-produced PAI-1 is
essential for cancer cell invasion and angiogenesis. The authors
(Ree et al, 1998) tried to explain the apparent paradox by
accepting that PAI-1 serves as a tumour promoter, e.g. by
protecting the tumour stroma, to which PAI-1 has been localized in
breast cancer lesions (Bianchi et al, 1995), from ongoing uPA-
mediated proteolysis. 
As shown recently (Takeha et al, 1997) in colon cancer, host
inflammatory cells expressing MMP-9 and uPAR were less preva-
lent in cases with liver metastasis than in cases without liver
metastasis. Furthermore, expression was lower in cases with an
infiltrating margin than in cases with an expanding margin. These
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Figure 2 Determination of optimal cut-off value of MMP-9 status for
prediction of relapse-free (A) and overall survival (B) of breast cancer
patients. The c2 values obtained at each cut-off-value are plotted against the
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5.61 and c2 = 6.74 RFS and OS, respectively). This cut-off (48th percentile)
identifies 52% of patients as being MMP-9 positive
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results indicate the presence of an inverse association between
matrix degrading proteinases and liver metastasis or infiltrating
growth pattern. The authors explain their data by proposing that
the immune/inflammatory reaction, forming a part of the host’s
defence mechanisms, is a significant source of matrix-degrading
proteinases. According to their report, MMP-9 was immunohisto-
chemically positive in macrophages and neutrophils, but negative
in cancer cells. The authors, however, do not exclude the possi-
bility that cancer cells are one of the major sources of MMP-9
protein, since results may vary depending on the epitopes of each
antibody used. In our study, MMP-9 staining was mainly observed
in cancer cells (~80%) and less in stromal fibroblasts,
macrophages and neutrophils, whereas Nielsen et al (1997)
showed that detectable amount of MMP-9 protein is absent from
cancer cells in ductal mammary carcinoma and is expressed only
in neutrophils, macrophages and vascular pericytes. Our findings
agree with the results of Visscher et al (1994) who found that 64%
of tumours showed staining of epithelial cells with the MMP-9
Mab, although he observed 20% of staining in patients with node
negative disease in contrast to our 49.4%. However, several MMPs
including gelatinase B / MMP-9 (Vu and Werb, 1998) are secreted
and mechanisms that enable their association with the cell
membrane are largely unknown. 
Recently Yu and Stamenkovic (1999) showed that CD44 serves
as an MMP-9 docking molecule to retain MMP-9 proteolytic
activity on the cell surface, providing evidence that CD44/MMP-9
Table 1 Relationship between MMP-9 status and other variables 
No. of patients (%) 
Variable Patients MMP-9 negative MMP-9 positive P value 
Age (years) 
<45 44 13 (29.5) 31 (70.5) 
45–55 39 24 (61.5) 15 (38.5) 0.011e
>55 127 63 (49.6) 64 (50.4) 
Tumour size (cm) 
≤2 48 23 (47.9) 25 (52.1) 
2–5 138 59 (42.8) 79 (57.2) 0.014e
>5 24 18 (75.0) 6 (25.0) 
Nodal status 
Negative 85 43 (50.6) 42 (49.4) 0.34f
Positive 116 54 (46.6) 62 (53.4) 
x9  
Gradea
I 9 4 (44.4) 5 (55.6) 
II 164 83 (50.6) 81 (49.4) 0.27e
III 29 10 (34.5) 19 (65.5) 
´ 8 
Histology 
Ductal 158 81 (51.3) 77 (48.7) 
Lobular 15 5 (33.3) 10 (66.7) 0.037e
Other 5 0 (0.0) 5 (100.0) 
´ 32 
Stageb
I 24 10 (41.7) 14 (58.3) 
II 135 58 (43.0) 77 (57.0) 0.009e
III–IV 47 32 (68.1) 15 (31.9) 
´ 4 
ER statusc
Negative 35 14 (40.0) 21 (60.0) 
Positive 151 70 (46.4) 81 (53.6) 0.19e
Strong positive 20 13 (65.0) 7 (35.0) 
´ 4 
PR statusc
Negative 28 20 (71.4) 8 (28.6) 
Positive 138 50 (36.2) 88 (63.8) <0.001e
Strong positive 40 27 (67.5) 13 (32.5) 
´ 4 
Cathepsin D statusd
Negative 104 53 (50.1) 51 (49.9) 0.21f
Positive 106 47 (44.3) 59 (55.7) 
Adjuvant treatment 
None 10 6 (60.0) 4 (40.0) 
Tamoxifen 124 66 (53.2) 58 (46.8) 0.057e
Chemotherapy ± tamoxifen 76 28 (36.8) 48 (63.2) 
aBloom–Richardson grading system; b TNM system; cNegative: < 10 fmol/mg; Positive: 10–300 fmol/mg;
Strong positive: > 300 fmol/mg. d Cut-off point: 60 pmol/mg; e c2 test; fFisher’s Exact Test. MMP-9 in breast cancer 1493
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complex formation is associated with tumor invasiveness in vivo.
Also, Sugiura et al (1998) upon examining the expression of
MMP-9 in human neuroblastoma revealed the presence of MMP-9
in stromal septa that separated nests of tumour cells. These septa
consisted of fibroblasts, vascular and perivascular cells, but not of
neuroblastic cells. They concluded that the matrix-degrading
proteolytic activity of a tumour is the result of a complex balance
between several factors including proMMP-9, active MMP-9,
MMPactivators, TIMPs and the balance is itself controlled by
interactions between tumour cells and host-derived stromal cells.
Recently, Mira et al (1999) showed that MMP-9 is expressed by
MCF-7 cells and is located on the cell surface as well as in the
conditioned medium. They hypothesized that IGF-1 promotes a
redistribution of an MMP-9 pool between the cell surface and the
medium and highlighted the importance of cell surface-anchored
MMP-9 activity in mediating IGF-1 chemoatractant activity. Also,
Remacle et al (1998), using gelatin zymography, found no signifi-
cant relationship between levels of either MMP-9 and breast
patient outcome, while a 50 kDa band in their zymogram was
associated with improved overall survival. Similarly, Visscher et al
(1994) found no relationship between levels of either MMP-2 or
MMP-9 and prognosis in breast cancer, while Daidone et al (1991)
found no association between collagenase IV levels and either
relapse-free survival or overall survival in axillary node-negative
breast cancer patients. Nevertheless, Pacheco et al (1998) reported
that overexpression of gelatinase B has a prognostic value for
breast cancer patients. 
In the present study, MMP-9-negativity was found more
frequently in the age cohort of 45 to 55 years which is the age with
the greater relative risk for relapse and death in relation to the ages
< 45 years (RR = 1.6) and > 55 years (RR = 3.2) (data not shown).
The expression of MMP-9 was positively associated in patients
with positive progesterone receptors (10 –300 fmol/mg protein),
but its expression was low in patients with strongly positive
estrogen or progesterone receptors (> 300 fmol/mg protein). With
regard to the latter observation, we have shown in the past that a
high concentration of estrogen or progesterone receptors indicates
poor prognosis in breast cancer (Ardavanis et al, 1997; Scorilas 
et al, 1999a, b). It has also been suggested by Thorpe et al (1993)
that tumours with extremely high levels of ER may indicate a
progression from a fully hormone-dependent to a hormone-
independent state, via hormone responsive phase. Moreover, in
vitro studies in other organs, such as the endometrium, have
suggested that progesterone can suppress the expression of MMPs,
although estradiol does not appear to directly activate their expres-
sion (Bruner et al, 1995). In the recent study by Salamonsen et al
(1997) progesterone withdrawal from the endometrium has the
potential both to increase the level of pro-MMP-1 within the tissue
and to change the balance between the MMPs and tissue inhibitors
of metalloproteinases that would be required for active tissue
degradation. 
We demonstrated in previous studies that the protease
Cathepsin-D is a marker of poor prognosis for node negative
breast cancer patients (Ardavanis et al, 1997; Scorilas et al,
1999a). In this study significant relationship between Cathepsin-D
and MMP-9 was not observed. The present study suggests that the
protease MMP-9 is a favourable prognosticator. In addition, the
proteases PSA (Yu et al, 1998) and Pepsinogen-C (Scorilas et al,
1999c) have also been characterized as favourable prognosticators
but for node positive breast cancer patients. In light of the fact that
not all hormone receptors are functional, the authors (Yu et al,
1998; Scorilas et al, 1999c) proposed that both proteases may
serve as better indicators of a functional pathway than the presence
of the steroid hormone receptors themselves. Because 30% of
node-negative breast cancer patients relapse, determination of
MMP-9 expression may help to separate patients with better 
Table 2 Association between MMP-9 expression and relapse-free and overall survival 
Relapse-free survival Overall survival 
MMP-9 status RRa 95% CIb P value RRa 95% CIb P value 
Univariate analysis
All patients (n = 206) 
MMP-9 negative 1.00 1.00 
MMP-9 positive 0.65 0.41–1.04 0.072 0.59 0.33–1.06 0.078 
Node-positive patients (n = 116) 
MMP-9 negative 1.00 1.00 
MMP-9 positive 0.89 0.47–1.67 0.73 1.14 0.49–2.96 0.63 
Node-negative patients (n = 85) 
MMP-9 negative 1.00 1.00 
MMP-9 positive 0.45 0.21–0.96 0.039 0.32 0.14–0.75 0.009 
Multivariate analysis c
All patients (n = 202) 
MMP-9 negative 1.00 1.00 
MMP-9 positive 0.89 0.49–1.61 0.71 0.78 0.35–1.75 0.55 
Node-positive patients (n = 113) 
MMP-9 negative 1.00 1.00 
MMP-9 positive 0.99 0.45–2.18 0.99 0.97 0.33–2.85 0.96 
Node-negative patientsd (n = 84) 
MMP-9 negative 1.00 1.00 
MMP-9 positive 0.23 0.04–1.31 0.098 0.47 0.24–0.94 0.034 
aRelative risk (RR) estimated from Cox proportional hazard regression model. bConfidence interval of the estimated RR.
cMultivariate models were adjusted for lymph nodes status; tumour size; patient age; cathepsin D; ER and PR expression. 
dIncluding also in the multivariate model the stage of the disease. 1494 A Scorilas et al
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prognosis and allow the use of different treatment modalities that
may exploit the function of protease inhibitors. 
Rha et al (1997) showed sequential production and activation of
MMP-9 with breast cancer progression. In both DCIS and T1
stage breast tumours they reported only 92 kDa (proMMP-9)
gelatinolytic activity as compared to non-cancerous tissue but they
found no difference in the 82 kDa (active form) activity among
them. In the present study we cannot distinguish between these
two events. The antibodies we used recognize the latent form of
the enzyme. It is likely that MMP-9 present in tumours from node-
negative patients is initially enzymatically inactive and as tumours
become more aggressive the balance shifts towards the active
form, thus the latent MMP-9 staining disappears. Present results
are in agreement with Garbett et al (1999) who found the latent
form of MMP-9 in both tumour and background breast tissues;
however, they found only the active form of this enzymes in
tumour tissue of paired samples. Furthermore, it is important to
consider that MMP-9 may be under regulation by steroid
hormones during mammary tumour progression, as the breast is a
hormone-responsive tissue. The precise signaling pathways medi-
ating MMP regulation by hormones are not well understood, but
have been shown to involve direct interaction with AP-1 transcrip-
tion factors in some cases (Jonat et al, 1990).
If expression of MMP-9 constitutes a host response to tumour
invasion, this may alter hormonal status by triggering series of yet
unknown pathways. Also, alteration to this protease may alter the
balance between host proteases and protease inhibitors produced
by the tumour cells enabling inhibition of matrix degradation and
tumour invasion. The possible reason for the apparently paradox-
ical association of MMP-9 positivity with better outcome may be
that in more aggressive tumors the MMP-9 may be in an active
state and therefore have a shorter half-life. There may also be a
greater amount of enzyme that is secreted (Hanemaaijer et al,
1999; Zucker et al, 1999) and not cell-associated and thus probably
transparent to immunohistochemistry. Although for assessment of
the role of MMPs in tumour progression, both enzyme and
inhibitor levels must be analysed. However, activation of the latent
precursor is also a key step in determining enzyme function in
vivo. For activation of proMMP-9, the serine proteases are thought
to be important and MT-MMP has been shown to be a potent acti-
vator of MMP-2. Jones et al (1999) examining immunohistochem-
ically MMP-9, MMP-2 their inhibitors and the activator MT1-MMP
reported a potentially important role for MT1-MMP which may be a
pivotal factor for controlling MMP-2 activity but showed no rela-
tionship for TIMP-1 to tumour grade or lymph node status. The
possible involvement of TIMPs/MT-MMPs is currently under inves-
tigation in our lab. Current therapeutic strategies using synthetic
inhibitors of MMPs have demonstrated clinical potential of regu-
lating protease activity and may be new targets for therapeutic
exploitation.
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